Tolerability, pharmacokinetics and pharmacodynamics of TA-8995, a selective cholesteryl ester transfer protein (CETP) inhibitor, in healthy subjects

导出原文传递

翻译打印收藏纠错

作者： Ford,J. ^[1] ; Lawson,M. ^[2] ; Fowler,D. ^[3] ; Maruyama,N. ^[4] ; Mito,S. ^[5] ; Tomiyasu,K. ^[6] ; Kinoshita,S. ^[7] ; Suzuki,C. ; Kawaguchi,A. ; Round,P. ; Boyce,M. ; Warrington,S. ; Weber,W. ; VanDeventer,S. ; Kastelein,J.J.P.

作者单位： Hammersmith Medicines Research, London, United Kingdom ^[1] Dezima Pharma BV, Gooimeer 2-35, Naarden, 1410 AD Naarden, Netherlands, Department of Vascular ^[2] Mitsubishi Pharma Europe Limited, London, United Kingdom ^[3] MPS Hamburg GmbH, Hamburg, Germany ^[4] Dezima Pharma BV, Gooimeer 2-35, Naarden, 1410 AD Naarden, Netherlands, Department of ^[5] Mitsubishi Tanabe Pharma Corporation, Tokyo, Japan ^[6] Dezima Pharma BV, Gooimeer 2-35, Naarden, 1410 AD Naarden, Netherlands, Xention Ltd, Cambridge ^[7]

关键词 apolipoproteins cardiovascular diseases cholesterol coronary disease hypercholesterolaemia

发布时间 2014-09-17

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交